Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Not yet scored
28.60 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Maze Therapeutics, Inc. holds its Markdown at $28.60. Consolidating, no directional conviction, held for 26 days.
As held on the ledger · 2026-08-27
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 26 days
Price at the screen
$28.60
Valuation
N/A trailing · -9.01 forward price to earnings
Values screen
Not scored· score 70.0
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.87%
Below 33%
Interest-bearing debt is just 5.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.56%
Below 33%
Cash held in interest-bearing accounts and securities is 4.6% of assets, under the one-third limit.
Pass
Receivables
47.65%
Below 49%
Money owed to the company is 47.7% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 92.3% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +92% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early kidney drug bets face binary odds
Picture a lab team racing to turn one molecule into a working pill for rare kidney disease before the cash runs out. Maze Therapeutics sits at that exact point, a clinical stage group with no sales, zero profit margin and a return on equity at minus 39 percent. The market prices the shares at roughly half our internal fair value, yet the opportunity rating stays at none because the business has yet to clear the first real proof point.
Forward earnings sit in negative territory and the moat remains unknown, which leaves the entire story resting on clinical data that may still fail. Eleven analysts call it a strong buy with a median target matching our number, but those forecasts assume success that has not been delivered. The ethical screen clears, yet that alone does not create an investable edge when the company burns cash to reach the next trial readout.
Risk sits in the usual biotech pattern of binary outcomes, dilution and long waits for any revenue. A single failed study can erase most of the apparent discount in weeks. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MAZE trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-04Markdown · changed$28.60+1.7%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter.
2026-08-05Accumulation$28.12+16.9%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 16.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63.
2026-07-18Accumulation$24.05+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63.
2026-07-03Accumulation$24.05+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$24.05Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
